{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:59:52Z","timestamp":1790312392734,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Sclerotic chronic graft-versus-host disease (Scl-cGVHD) is a disabling fibrotic manifestation of cGVHD and frequently exhibits poor responsiveness to conventional immunosuppressive therapy. Therapeutic options remained limited, particularly in pediatric patients. An 8-year-old boy with relapsed acute myeloid leukemia underwent matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) in January 2021. Four months later, he developed progressive cutaneous cGVHD that evolved into severe Scl-cGVHD, with diffuse skin thickening, painful fissures, ulceration, and multiple joint contractures, loss of independent ambulation, and complete dependence in activities of daily living. Skin biopsy demonstrated extensive dermal fibrosis, collagen deposition, and increased\n                    <jats:italic>\u03b1<\/jats:italic>\n                    -smooth muscle actin (\n                    <jats:italic>\u03b1<\/jats:italic>\n                    -SMA) expression. Despite multiple lines of immunosuppressive and targeted therapy, including corticosteroids, calcineurin inhibitors, mycophenolate mofetil, ruxolitinib, rituximab, and other agents, the disease progressed, with the modified Rodnan skin score (mRSS) reaching 35. Because of refractory disease and disabling disease, a second haploidentical HSCT from his father was performed in September 2022. Following transplantation, disease progression ceased and gradual clinical improvement occurred. At 12 months, the mRSS decreased from 35 to 2, with substantial recovery of skin flexibility and joint mobility. Repeat skin biopsy showed reduced collagen compactness and markedly decreased interstitial\n                    <jats:italic>\u03b1<\/jats:italic>\n                    -SMA expression, consistent with attenuation and remodeling of dermal fibrosis. Serial immune monitoring revealed progressive recovery of B- and NK-cell compartments and sustained T-cell reconstitution after the second transplantation, in contrast to prolonged B-cell depletion and limited NK-cell recovery after the first transplant. At 24 months, complete donor chimerism persisted, leukemia remained in remission, the mRSS reached 0, and the patient regained independent walking and activities of daily living. This case describes sustained clinical regression and histopathological attenuation of severe, established Scl-cGVHD following a second haploidentical HSCT. The temporal association with immune reconstitution raises the possibility that restoration of immune homeostasis may have contributed to disease remodeling. However, causality cannot be established from a single case. Given the substantial risks associated with second allo-HSCT, this approach should not be considered standard therapy and may be considered only in exceptional, highly selected patients after multidisciplinary risk-benefit assessment.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1929283","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:18Z","timestamp":1790310378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Regression of severe sclerotic chronic graft-versus-host disease after a second haploidentical hematopoietic stem cell transplantation: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Rongmu","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital","place":["Beijing, China"]},{"name":"Department of Hematology, China Aerospace Science & Industry Corporation 731 Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, China Aerospace Science & Industry Corporation 731 Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexian","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology, China Aerospace Science & Industry Corporation 731 Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"504 e1","DOI":"10.1016\/j.jtct.2020.12.027","article-title":"Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis","volume":"27","author":"Bachier","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0190-9622(92)70005-z","article-title":"Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases","volume":"26","author":"Chosidow","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"B5","first-page":"258","article-title":"Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome","volume":"91","author":"Skert","year":"2006","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/blood-2012-10-464198","article-title":"Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","article-title":"Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease","volume":"118","author":"Martires","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2023.6277","article-title":"Patient-reported outcomes and mortality in cutaneous chronic graft-vs-host disease","volume":"160","author":"Baumrin","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaad.2025.10.018","article-title":"Reduction in sclerotic graft-versus-host-disease after post-transplant cyclophosphamide-based regimen compared to traditional tacrolimus-based regimens in allogeneic hematopoietic cell transplant recipients: a retrospective cohort study","volume":"94","author":"Peacker","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jtct.2021.06.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: iV. The 2020 highly morbid forms report","volume":"27","author":"Wolff","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1200\/JCO.24.00205","article-title":"A multicenter phase II trial of ruxolitinib for treatment of corticosteroid refractory sclerotic chronic graft-versus-host disease","volume":"42","author":"Bhatt","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1182\/bloodadvances.2024014387","article-title":"Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD","volume":"9","author":"Hong","year":"2025","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3389\/fimmu.2019.02516","article-title":"Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation","volume":"10","author":"Chang","year":"2019","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1182\/blood-2012-04-347286","article-title":"Effect of MHC and non-MHC donor\/recipient genetic disparity on the outcome of allogeneic HCT","volume":"120","author":"Warren","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101555","DOI":"10.1016\/j.beha.2024.101555","article-title":"Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation","volume":"37","author":"Fuchs","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jtct.2025.07.013","article-title":"Molecular disparity of HY antigen affects chronic graft-versus-host disease and relapse in female-to-male stem cell transplants","volume":"31","author":"Saliba","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.mcb.2024.05.011","article-title":"Identification and analysis of alloreactive T lymphocytes from peripheral blood mononuclear cells","volume":"189","author":"Susana","year":"2024","journal-title":"Methods Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/MOH.0b013e328353bc7d","article-title":"Immune reconstitution after hematopoietic cell transplantation","volume":"19","author":"Bosch","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.13311","article-title":"B-cell involvement in chronic graft-versus-host disease","volume":"93","author":"Kapur","year":"2008","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1005031","DOI":"10.3389\/fimmu.2022.1005031","article-title":"Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"13","author":"Mushtaq","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1045168","DOI":"10.3389\/fimmu.2022.1045168","article-title":"Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease","volume":"13","author":"Doglio","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","article-title":"Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease","volume":"113","author":"Sarantopoulos","year":"2009","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1182\/blood-2011-05-354787","article-title":"Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific","volume":"118","author":"Amir","year":"2011","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"954268","DOI":"10.3389\/fimmu.2022.954268","article-title":"Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis","volume":"13","author":"Fan","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","article-title":"A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease","volume":"112","author":"Flowers","year":"2008","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"107387","DOI":"10.1016\/j.leukres.2023.107387","article-title":"Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure","volume":"134","author":"Linn","year":"2023","journal-title":"Leuk Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S513","DOI":"10.1016\/j.jtct.2024.05.020","article-title":"Cutaneous chronic graft-versus-host disease: clinical manifestations, diagnosis, management, and supportive care","volume":"30","author":"Shi","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","first-page":"644.e1","DOI":"10.1016\/j.jtct.2026.01.009","article-title":"Toward better response assessment of cutaneous chronic graft-versus-host disease: a report from the national institutes of health consensus project task force","volume":"32","author":"Markova","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1111\/bjd.15593","article-title":"Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease","volume":"177","author":"Hurabielle","year":"2017","journal-title":"Br J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.aab3388","article-title":"Stem cells and healthy aging","volume":"350","author":"Goodell","year":"2015","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbmt.2014.10.029","article-title":"B cells in chronic graft-versus-host disease","volume":"21","author":"Sarantopoulos","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5152\/TurkArchPediatr.2025.24334","article-title":"Hematopoietic stem cell transplantation in severe combined immunodeficiency at the pediatric intensive care unit: case series of 5 severe combined immunodeficiency patients","volume":"61","author":"\u00d6zt\u00fcrk","year":"2025","journal-title":"Turk Arch Pediatr"},{"key":"B47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.65717\/TurkArchPediatr.2026.25004","article-title":"Juvenile localized scleroderma with cutaneous and extracutaneous involvement: long-term observational outcomes from a referral center","volume":"61","author":"Kilic Konte","year":"2026","journal-title":"Turk Arch Pediatr"},{"key":"B48","doi-asserted-by":"publisher","first-page":"767 e1","DOI":"10.1016\/j.jtct.2022.08.008","article-title":"Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis","volume":"28","author":"Kharfan-Dabaja","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-019-0251-3","article-title":"Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the acute leukemia working party of EBMT","volume":"9","author":"Shimoni","year":"2019","journal-title":"Blood Cancer J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","article-title":"Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1","volume":"1","author":"Versluis","year":"2017","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.bbmt.2016.06.026","article-title":"T cell-replete HLA haploidentical donor transplantation with post-transplant cyclophosphamide is an effective salvage for patients relapsing after an HLA-matched related or matched unrelated donor transplantation","volume":"22","author":"Gorgeis","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/bmt.2014.83","article-title":"Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation","volume":"49","author":"Tischer","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.v98.2.489","article-title":"Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation","volume":"98","author":"Storek","year":"2001","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1929283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:20Z","timestamp":1790310380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1929283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":53,"alternative-id":["10.3389\/fmed.2026.1929283"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1929283","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1929283"}}